Adhering to the principles of clinical pharmacology - the correct fixed combinations of antihypertensive drugs.
Hypertension is one of the primary modifiable risk factor for cardiac and renal diseases with the prevalence around 30-45% of the general population, with a steep increase with ageing. The administration of blood pressure-lowering drugs is to reduce the risk of major clinical cardiovascular outcomes. Hypertension guidelines recommend combination therapy in patients with high cardiovascular risk and with subclinical organ damage as well as when monotherapy fails. Areas covered: As the etiology of essential hypertension is multifactorial, combination therapy using different classes of antihypertensive agents have greater effect than each on its own (synergistic effect), may have better tolerability (two components minimizing each other's side effects) and lead to improved patient compliance. Several studies assess the hypotensive efficacy on drug combination; there are also studies on triple drug combination. Expert commentary: At present, dual and triple combination therapy is available to hypertensive patients with good clinical outcomes, compliance and low profile of side effects. It is critical as patients' adherence to the pharmacological therapy significantly decreases the risk of long-term adverse events including mortality. It appears that combinations not only of hypotensive drugs but also with statins (as well as antidiabetics) will be widely used.
['Lopatowska|Paulina|P|', 'Mlodawska|Elzbieta|E|', 'Tomaszuk-Kazberuk|Anna|A|', 'Banach|Maciej|M|', 'Malyszko|Jolanta|J|']
D000959:Antihypertensive Agents D001794:Blood Pressure D002318:Cardiovascular Diseases D004338:Drug Combinations D004357:Drug Synergism D004359:Drug Therapy, Combination D006801:Humans D006973:Hypertension D055118:Medication Adherence D017410:Practice Guidelines as Topic D012307:Risk Factors
Antihypertensive drugs combination therapy single pill combination